Cisplatin nephrotoxicity affects magnesium and calcium metabolism
Medical and Pediatric Oncology · 2003-09 · 41 (3) · 186-189
DOI: 10.1002/mpo.10335 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical and Pediatric Oncology, online erschienen am 11.07.2003. Verfasst von Marshall P Goren. Beteiligte Einrichtung: Department of Urology, The University of Tennessee, Memphis, Tennessee, USA. mgoren@utmem.edu. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: PHS HHS.
Abstract (Originalsprache)
Cisplatin is not directly toxic to bone, but cisplatin nephrotoxicity leading to magnesium wasting may affect magnesium and calcium metabolism, both of which contribute to bone integrity. The specificity of the magnesium lesion suggests that cisplatin may have an affinity for proteins that regulate magnesium absorption. Sulfhydryls such as amifostine can reduce the toxicity of cisplatin in adults, but current pediatric data do not indicate a role for sulfhydryl therapy to reduce cisplatin toxicity in children. Med Pediatr Oncol 2003;41:186–189, © 2003 Wiley‐Liss, Inc.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, The University of Tennessee, Memphis, Tennessee, USA. mgoren@utmem.edu
Förderung
- PHS HHS
Zitieren
APA
Goren, M. P. (2003). Cisplatin nephrotoxicity affects magnesium and calcium metabolism. Medical and Pediatric Oncology, 41(3), 186-189. https://doi.org/10.1002/mpo.10335
Vancouver
Goren MP. Cisplatin nephrotoxicity affects magnesium and calcium metabolism. Medical and Pediatric Oncology. 2003;41(3):186-189. doi:10.1002/mpo.10335
BibTeX
@article{Goren2003,
author = {Goren, Marshall P},
title = {Cisplatin nephrotoxicity affects magnesium and calcium metabolism},
journal = {Medical and Pediatric Oncology},
year = {2003},
volume = {41},
number = {3},
pages = {186--189},
doi = {10.1002/mpo.10335}
}
EUVIMED